


Claims

1. A pharmaceutically-acceptable acid addition salt of a compound of formula I,



wherein

R¹ represents C₁₋₂ alkyl substituted by one or more fluoro substituents;

R² represents C₁₋₂ alkyl; and

10 n represents 0, 1 or 2.

2. An acid addition salt as claimed in claim 1, wherein the acid is a sulfonic acid.
3. An acid addition salt as claimed in claim 1 or claim 2, wherein the acid is ethanesulfonic acid, *n*-propanesulfonic acid, benzenesulfonic acid, 1,5-naphthalenedisulfonic acid, or *n*-butanesulfonic acid.
4. An acid addition salt as claimed in any one of claims 1 to 3, wherein R¹ represents -OCHF₂ or -OCH₂CH₂F.
5. An acid addition salt as claimed in any one of claims 1 to 4, wherein R² represents methyl.
6. An acid addition salt as claimed in any one of claims 1 to 5, wherein *n* represents 0 or 2.

7. An acid addition salt as claimed in any one of claims 1 to 6, wherein the compound of formula I is

Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) or
Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe).

5

8. An acid addition salt as claimed in any one of claims 1 to 7 in substantially crystalline form.

9. An acid addition salt as claimed in any one of claims 1 to 7 in partially crystalline form.

10

10. An acid addition salt as claimed in any one of claims 1 to 8, wherein n represents 0, in substantially crystalline form.

11. An acid addition salt as claimed in any one of claims 1 to 7 or claim 9, wherein n represents 2, in partially crystalline form.

15

12. An acid addition salt as claimed in any one of claims 1 to 8 or claim 10, which is Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) benzene-sulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 5.9, 4.73, 4.09 and 4.08Å.

20

13. An acid addition salt as claimed in any one of claims 1 to 7, claim 9 or claim 11, which is

Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe) hemi-1,5-naphthalenedisulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 18.3, 9.1, 5.6, 5.5, 4.13, 4.02, 3.86, 3.69 and 3.63Å.

25

14. A process for the preparation of an acid addition salt as claimed in any one of claims 1 to 13, which process comprises addition of an acid to a compound of formula I as defined in claim 1.

5 15. A process for the preparation of an acid addition salt, as claimed in claim 14, which process comprises crystallising an acid addition salt as described in any one of claims 1 to 13.

10 16. A pharmaceutical formulation comprising an acid addition salt, as claimed in any one of claims 1 to 13, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

15 17. An acid addition salt, as claimed in any one of claims 1 to 13, for use in the treatment of a condition where inhibition of thrombin is required.

18. The use of an acid addition salt, as claimed in any one of claims 1 to 13, as an ingredient for the manufacture of a medicament for the treatment of a condition where inhibition of thrombin is required.

20 19. A method of treatment of a condition where inhibition of thrombin is required which method comprises administration of a therapeutically effective amount of an acid addition salt, as claimed in any one of claims 1 to 13, to a person suffering from, or susceptible to, such a condition.